Preparation and immunological evaluation of inactivated avian influenza virus vaccine encapsulated in chitosan nanoparticles

Efficacy maximization of inactivated avian influenza vaccine using safe adjuvants was investigated. Chitosan nanoparticles were prepared by ionic gelation method with average size of 150 nm and their Zeta potential was 11.5 mV. After encapsulation of avian influenza vaccine, the average size was 397 nm and Zeta potential was 4.29 mV. The highest HI antibody titer results were shown in chicken group vaccinated with inactivated avian influenza virus AIV-chitosan followed by the group vaccinated with inactivated AIV-chitosan nanoparticles then the group vaccinated with oil inactivated AIV vaccine, on using chicken antigen at 2 weeks post second vaccination. Upon using duck antigen, the highest HI antibody titers were shown in chicken group vaccinated with inactivated AIV oil emulsion vaccine followed by chicken group vaccinated with AIV-chitosan nanoparticles then the group vaccinated with AIV–chitosan. Chicken in the group vaccinated with AIV-chitosan nanoparticles induced the best results of lymphocyte proliferation assay. The results of phagocytic activity percentage and phagocytic index of AIV-chitosan nanoparticles and AIV–chitosan groups at 3 days post first vaccination were increased significantly in comparison with other groups, whereas at 14 days post first vaccination, group vaccinated with AIV-chitosan nanoparticles showed significant increase in phagocytic activity percentage and phagocytic index. [Display omitted]